文献速递前列腺癌

单平面双参数与多参数磁共振在前列腺癌诊断中的随机非劣效试验

Diagnostic Accuracy of Single-plane Biparametric and Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Randomized Noninferiority Trial in Biopsy-naïve Men.
PubMed 文献 · Eur Urol Oncol · 2021-04-21

在311例未活检、年龄≤75岁、PSA≤15 ng/ml且直肠指检阴性的男性中,随机分配至1.5-T快速MRI(n=213)或多参数MRI(n=98)。快速MRI组临床显著前列腺癌检出率为23.5%(50/213,95%CI 18.0-29.8%),多参数MRI组为32.7%(32/98,95%CI 23.6-42.9%),差异9.2%(p=0.09)。快速MRI在可疑病例序贯多参数MRI的策略对临床显著前列腺癌检出不劣于多参数MRI。

要点

  • 快速MRI序贯多参数MRI策略对临床显著前列腺癌检出不劣于多参数MRI。
  • 快速MRI组检出率23.5%,多参数MRI组32.7%,差异9.2%(p=0.09)。
  • 研究限于单中心,年龄≤75岁、PSA≤15 ng/ml且直肠指检阴性人群。

核心结论

  • 在未活检男性中,快速MRI可疑时序贯多参数MRI对临床显著前列腺癌的检出不劣于多参数MRI。

研究设计与样本

  • 随机非劣效试验,2018年4月至2020年2月纳入311例未活检男性,年龄≤75岁,PSA≤15 ng/ml,直肠指检阴性。
  • 随机分配至1.5-T快速MRI(n=213)或多参数MRI(n=98)。
  • 所有MRI按PI-RADS v2分类,快速MRI PI-RADS 1-2行12针系统活检,快速MRI PI-RADS 4-5或多参数MRI PI-RADS 3-5行靶向联合系统活检,快速MRI PI-RADS 3行多参数MRI后根据结果活检。

主要发现

  • 快速MRI组临床显著前列腺癌检出率为23.5%(50/213,95%CI 18.0-29.8%)。
  • 多参数MRI组临床显著前列腺癌检出率为32.7%(32/98,95%CI 23.6-42.9%)。
  • 两组检出率差异为9.2%(p=0.09)。

关键数值与推荐

  • 非劣效界值设定为10%差异。
  • 主要结局为比较两组临床显著前列腺癌检出率。
  • 次要结局为评估PSA密度在快速MRI不确定病例中排除活检的作用。

临床怎么用

  • 对于未活检、年龄≤75岁、PSA≤15 ng/ml且直肠指检阴性的男性,可采用快速MRI序贯多参数MRI策略诊断临床显著前列腺癌。
  • 快速MRI不确定(PI-RADS 3)时行多参数MRI并根据结果决定活检。

局限性

  • 单中心研究可能影响可重复性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Urological guidelines recommend multiparametric magnetic resonance imaging (mpMRI) in men with a suspicion of prostate cancer (PCa). The resulting increase in MRI demand might place health care systems under substantial stress. OBJECTIVE: To determine whether single-plane biparametric MRI (fast MRI) workup could represent an alternative to mpMRI in the detection of clinically significant (cs) PCa. DESIGN, SETTING, AND PARTICIPANTS: Between April 2018 and February 2020, 311 biopsy-naïve men aged ≤75 yr with PSA ≤15 ng/ml and negative digital rectal examination were randomly assigned to 1.5-T fast MRI (n = 213) or mpMRI (n = 98). INTERVENTION: All MRI examinations were classified according to Prostate Imaging-Reporting and Data System (PI-RADS) version 2. Men scored PI-RADS 1-2 underwent 12-core standard biopsy (SBx) and those with PI-RADS 4-5 on fast MRI or PI-RADS 3-5 on mpMRI underwent targeted biopsy in combination with SBx. Equivocal cases on fast MRI (PI-RADS 3) underwent mpMRI and then biopsy according to the findings. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was to compare the detection rate of csPCa in both study arms, setting a 10% difference for noninferiority. The secondary outcome was to assess the role of prostate-specific antigen density (PSAD) in ruling out men who could avoid biopsy among those with equivocal findings on fast MRI. RESULTS AND LIMITATIONS: The overall MRI detection rate for csPCa was 23.5% (50/213; 95% confidence interval [CI] 18.0-29.8%) with fast MRI and 32.7% (32/98; 95% CI 23.6-42.9%) with mpMRI (difference 9.2%; p = 0.09). The reproducibility of the study could have been affected by its single-center nature. CONCLUSIONS: Fast MRI followed by mpMRI in equivocal cases is not inferior to mpMRI in the detection of csPCa among biopsy-naïve men aged ≤75 yr with PSA ≤15 ng/ml and negative digital rectal examination. These findings could pave the way to broader use of MRI for PCa diagnosis. PATIENT SUMMARY: A faster MRI (magnetic resonance imaging) protocol with no contrast agent and fewer scan sequences for examination of the prostate is not inferior to the typical MRI approach in the detection of clinically significant prostate cancer. If our findings are confirmed in other studies, fast MRI could represent a time-saving and less invasive examination for men with suspicion of prostate cancer. This trial is registered at ClinicalTrials.gov as NCT03693703.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Russo F, Mazzetti S, Regge D, et al. Diagnostic Accuracy of Single-plane Biparametric and Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Randomized Noninferiority Trial in Biopsy-naïve Men. Eur Urol Oncol. 2021. PMID: 33893066. doi:10.1016/j.euo.2021.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。